Australia’s regulatory authorities have cleared Milestone Scientific, Inc., to market its epidural and intra-articular instruments and disposables in Australia.
Novel Epidural/Intra-articular Device Cleared in Australia
1 min read Premium comments
Secondary
According to the firm’s press release, Milestone’s Dynamic Pressure Sensing® capability in the CompuFlo® Epidural instrument “provides feedback that allows anesthesiologists to correctly identify the epidural space. This has the potential to significantly reduce complications and malpractice compared to conventional techniques.” DPS technology is incorporated into the CompuFlo® Intra-Articular instrument to provide precise computerized drug injections into intra-articular joint spaces in osteoarthritis patients.
Milestone Scientific CEO Leonard Osser stated, “We are pleased to announce regulatory marketing clearance to sell our epidural and intra-articular instruments and disposables in Australia. Australia represents a sizable market for our technology with approximately 1.8 million residents with osteoarthritis. The CompuFlo® Epidural and Intra-Articular instruments provide new clinical tools to enhance the safety and reduce pain associated with epidural and intra-articular procedures.”
Milestone Scientific Inc. located in Livingstone, New Jersey, is a medical research and development company that designs and patents innovative injection technology. According to company officials, Milestone’s computer-controlled systems make injections precise, efficient, and virtually painless.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.